Clovis Oncology, Inc., a biotech formed by Pharmion execs to develop pancreas and lung cancer drugs, will see its quiet period end on December 26. On November 15, the company raised $130 million by offering 10 million shares at $13, at the low end of the range of $13 to $15. J.P. Morgan and Credit Suisse acted as lead managers on the deal.
